Cinnabaris Biopharma

Cinnabaris Biotech is an emerging biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company leverages a proprietary ADC technology platform to create precision therapies with enhanced efficacy and safety profiles. Cinnabaris Biotech has established strategic partnerships with major industry players, including Celltrion and WuXi XDC, to accelerate its research and development strategy. These collaborations focus on advancing a pipeline of innovative bioconjugates through clinical development and manufacturing. The company is positioned as a key player in the rapidly evolving oncology landscape, particularly in the field of targeted drug delivery.